Literature DB >> 22684157

Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age.

Rajan Wadhawan1, William Oh, Betty R Vohr, Shampa Saha, Abhik Das, Edward F Bell, Abbott Laptook, Seetha Shankaran, Barbara J Stoll, Michele C Walsh, Rose Higgins.   

Abstract

BACKGROUND: Spontaneous intestinal perforation (SIP) is associated with the use of postnatal glucocorticoids and indometacin in extremely low birth weight (ELBW) infants. The authors hypothesised: 1) an association of SIP with the use of antenatal steroids (ANS) and indometacin either as prophylaxis for intraventricular hemorrhage (IVH) (P Indo) or for treatment of PDA (Indo/PDA) and 2) an increased risk of death or abnormal neurodevelopmental outcomes in infants with SIP at 18-22 months corrected age. DESIGN/
METHODS: The authors retrospectively identified ELBW infants with SIP in the Neonatal Research Network's generic database. Unadjusted analysis identified the differences in maternal, neonatal and clinical variables between infants with and without SIP. Logistic regression analysis identified the adjusted OR for SIP with reference to ANS, P Indo and Indo/PDA. Neurodevelopmental outcomes were assessed among survivors at 18-22 months corrected age.
RESULTS: Indo/PDA was associated with an increased risk of SIP (adjusted OR 1.61; 95% CI 1.25 to 2.08), while P Indo and ANS were not. SIP was independently associated with an increased risk of death or neurodevelopmental impairment (NDI) (adjusted OR 1.85; 95% CI 1.32 to 2.60) and NDI among survivors (adjusted OR 1.75, 95% CI 1.20 to 2.55).
CONCLUSION: Indometacin used for IVH prophylaxis and ANS were not associated with the occurrence of SIP in ELBW infants. Indometacin used for treatment of symptomatic PDA was however associated with an increased risk of SIP. ELBW infants with SIP have an increased risk of poor neurodevelopmental outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684157      PMCID: PMC3753803          DOI: 10.1136/archdischild-2011-300659

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  24 in total

1.  Weighing statistical certainty against ethical, clinical, and biologic expediency: the contributions of the Watterberg trial tip the scales in the right direction.

Authors:  Phillip V Gordon
Journal:  Pediatrics       Date:  2005-05       Impact factor: 7.124

2.  Localized intestinal perforation following intravenous indomethacin for patent ductus arteriosus.

Authors:  T D Scholz; G A McGuinness
Journal:  J Pediatr Gastroenterol Nutr       Date:  1988 Sep-Oct       Impact factor: 2.839

3.  Spontaneous focal gastrointestinal perforation in very low birth weight infants.

Authors:  J L Aschner; K S Deluga; L A Metlay; R W Emmens; K D Hendricks-Munoz
Journal:  J Pediatr       Date:  1988-08       Impact factor: 4.406

4.  Localized intestinal perforations after enteral administration of indomethacin in premature infants.

Authors:  G Alpan; F Eyal; I Vinograd; R Udassin; G Amir; P Mogle; B Glick
Journal:  J Pediatr       Date:  1985-02       Impact factor: 4.406

5.  Discharge outcomes of extremely low birth weight infants with spontaneous intestinal perforations.

Authors:  J T Attridge; A C Herman; M J Gurka; M P Griffin; E D McGahren; P V Gordon
Journal:  J Perinatol       Date:  2006-01-01       Impact factor: 2.521

6.  Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial.

Authors:  Kristi L Watterberg; Jeffrey S Gerdes; Cynthia H Cole; Susan W Aucott; Elizabeth H Thilo; Mark C Mammel; Robert J Couser; Jeffery S Garland; Henry J Rozycki; Corinne L Leach; Conra Backstrom; Michele L Shaffer
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

7.  Necrotizing enterocolitis among neonates in the United States.

Authors:  Scott O Guthrie; Phillip V Gordon; Victor Thomas; James A Thorp; Joyce Peabody; Reese H Clark
Journal:  J Perinatol       Date:  2003-06       Impact factor: 2.521

8.  Spontaneous intestinal perforation in premature infants: a distinct clinical entity associated with systemic candidiasis.

Authors:  E E Adderson; A Pappin; A T Pavia
Journal:  J Pediatr Surg       Date:  1998-10       Impact factor: 2.545

9.  Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants.

Authors:  Jiun Lee; Victor Samuel Rajadurai; Keng Wee Tan; Keng Yean Wong; Ee Hwee Wong; Joy Yoke Ngan Leong
Journal:  Pediatrics       Date:  2003-08       Impact factor: 7.124

10.  Spontaneous, isolated intestinal perforations in neonates with birth weight less than 1,000 g not associated with necrotizing enterocolitis.

Authors:  C L Meyer; N R Payne; S A Roback
Journal:  J Pediatr Surg       Date:  1991-06       Impact factor: 2.545

View more
  16 in total

1.  Intestinal perforation in very preterm neonates: risk factors and outcomes.

Authors:  J Shah; N Singhal; O da Silva; N Rouvinez-Bouali; M Seshia; S K Lee; P S Shah
Journal:  J Perinatol       Date:  2015-04-30       Impact factor: 2.521

2.  Effect of prophylactic indomethacin administration and early feeding on spontaneous intestinal perforation in extremely low-birth-weight infants.

Authors:  M Stavel; J Wong; Z Cieslak; R Sherlock; M Claveau; P S Shah
Journal:  J Perinatol       Date:  2016-10-20       Impact factor: 2.521

3.  Management of neonatal spontaneous intestinal perforation by peritoneal needle aspiration.

Authors:  M Gébus; J-L Michel; S Samperiz; L Harper; J-L Alessandri; D Ramful
Journal:  J Perinatol       Date:  2017-11-09       Impact factor: 2.521

4.  Definitive peritoneal drainage in the extremely low birth weight infant with spontaneous intestinal perforation: predictors and hospital outcomes.

Authors:  B M Jakaitis; A M Bhatia
Journal:  J Perinatol       Date:  2015-04-09       Impact factor: 2.521

5.  A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants.

Authors:  J M Davidson; J Ferguson; E Ivey; R Philip; M F Weems; A J Talati
Journal:  J Perinatol       Date:  2020-05-21       Impact factor: 2.521

6.  Patent ductus arteriosus and spontaneous intestinal perforation in a cohort of preterm infants.

Authors:  Alessandra Mayer; Gaia Francescato; Nicola Pesenti; Federico Schena; Fabio Mosca
Journal:  J Perinatol       Date:  2022-05-19       Impact factor: 2.521

Review 7.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

8.  Pharmacogenetics in clinical pediatrics: challenges and strategies.

Authors:  Sara L Van Driest; Tracy L McGregor
Journal:  Per Med       Date:  2013-09       Impact factor: 2.512

Review 9.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

10.  Prophylactic indomethacin and intestinal perforation in extremely low birth weight infants.

Authors:  John Kelleher; Ariel A Salas; Ramachandra Bhat; Namasivayam Ambalavanan; Shampa Saha; Barbara J Stoll; Edward F Bell; Michele C Walsh; Abbot R Laptook; Pablo J Sánchez; Seetha Shankaran; Krisa P VanMeurs; Ellen C Hale; Nancy S Newman; M Bethany Ball; Abhik Das; Rosemary D Higgins; Myriam Peralta-Carcelen; Waldemar A Carlo
Journal:  Pediatrics       Date:  2014-10-27       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.